Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-2019 infections vaccine - Generex Biotechnology

Drug Profile

COVID-2019 infections vaccine - Generex Biotechnology

Alternative Names: 'Ii-Key-nCOV peptide vaccine - Generex Biotechnology; SARS-CoV-2 virus vaccines - Generex Biotechnology

Latest Information Update: 22 May 2020

At a glance

  • Originator Generex Biotechnology Corporation
  • Class Peptide vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 04 May 2020 Generex Biotechnology submit proposal to Biomedical Advanced Research and Development Authority to finance and support development of COVID-2019 vaccine programme
  • 19 Apr 2020 Generex Biotechnology is collaborating with private collaborators and academic experts to evaluate a number of peptide vaccine candidates for future clinical use
  • 19 Apr 2020 Generex Biotechnology is seeking partnership from USA and international government for the clinical development and manufacturing of COVID-19 infection vaccine

Development Overview

Introduction

COVID-2019 infections vaccine is being developed by Generex Biotechnology for the preventive treatment of coronavirus infection (COVID-19 strain). The company will utilise li-Key peptide vaccine platform of NuGenerex Immune-Oncology (subsidiary of Generex Biotechnology). Major histocompatibility complex (MHC) class II associated invariant chain (Ii) derived Ii-Key peptide is involved in the regulation of the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. When the peptide is linked to an antigenic epitope, it displaces the resident antigens from the antigen binding grove on MHC Class II molecules. This renders the MHC molecules to present the Ii-Key epitope to selectively activate T-helper type 1 cells responses. These events increase the duration and intensity of the immune responses. The interaction reduces the binding affinity of the antigenic binding groove on the MHC class II molecule and any previously resident epitope is discharged. Early research is underway in China and the US.

Company Agreements

In March 2020, Generex Biotechnology entered into a licensing agreement with Beijing Zhonghua Investment Fund Management and Sinotek-Advocates International Industry Development for the development of coronavirus vaccine (COVID-19 strain), using the Ii-Key peptide vaccine platform of NuGenerex immune-Oncology (NGIO), a Generex’s majority owned subsidiary. According to the terms of the agreement Ii-Key peptides linked with nCOV-2019 coronavirus epitopes will be generated by Generex Biotechnology through NGIO and will be tested against the blood samples of the patients in China recovered from coronavirus infection by the Chinese partners. The data obtained will indicate the Ii-Key-nCOV epitopes recognised by the human immune system, that will eventually be developed as the potential coronavirus vaccine by Generex Biotechnology. The human clinical trials will be conducted in China and the USA. The Chinese partners will have exclusive rights to use and commercialise the products in China and will make payments to Generex Biotechnology that include upfront payment of USD$ 1 million, development expenses, royalty on each dose of vaccine produced and $USD 5 million as a licensing fee for the Ii-Key technology upon completion of development and testing. Generex Biotechnology will may payments to NuGenerex Immuno-Oncology after the receipt of the licensing payments, since the intellectual property resides with the later. [1]

In August 2019, Generex Biotechnology announced for a planned spin-out of its subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express), which will include the Ii-Key technology and AE37 immunotherapeutic vaccine program. Based on this spin-out, NuGenerex Immuno-Oncology will separate and work as a public company. [2]

Key Development Milestones

In May 2020, Generex Biotechnology submitted a contract proposal to Biomedical Advanced Research and Development Authority (BARDA) to fund and support the development of a COVID-2019 vaccine against the SARS-CoV-2 coronavirus using the Ii-Key vaccine technology [3] .

In May 2020, Generex Biotechnology completed identification and selection of SARS-CoV-2 epitopes for development of vaccines. The company also commenced GLP manufacturing of synthetic Ii-Key-SARS-CoV-2 peptides for screening in ex vivo assays like cellular assays, antibody and virus neutralisation tests, and a in vitro cytokine storm cellular assay, using blood samples from COVID-2019 convalescent patients, in order to assess and select Ii-Key peptides that activate the immune system [3] .

Generex Biotechnology has initiated early research in coronavirus infections in China and the US [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Peptide vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research China, USA Parenteral / unspecified Generex Biotechnology Corporation 09 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Generex Biotechnology Corporation Originator Canada
Generex Biotechnology Corporation Owner Canada
Beijing Zhonghua Investment Fund Management Co., LTD Licensee China
Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD Licensee China
NuGenerex Immuno-Oncology Technology Provider USA

Development History

Event Date Update Type Comment
04 May 2020 Company Involvement Generex Biotechnology submit proposal to Biomedical Advanced Research and Development Authority to finance and support development of COVID-2019 vaccine programme [3] Updated 22 May 2020
19 Apr 2020 Licensing Status Generex Biotechnology is collaborating with private collaborators and academic experts to evaluate a number of peptide vaccine candidates for future clinical use Updated 08 May 2020
19 Apr 2020 Licensing Status Generex Biotechnology is seeking partnership from USA and international government for the clinical development and manufacturing of COVID-19 infection vaccine Updated 08 May 2020
19 Apr 2020 Regulatory Status Generex Biotechnology is in discussion with health Canada to evaluate regulatory path for the approval of COVID-19 infections vaccines in Canada Updated 08 May 2020
16 Mar 2020 Trial Update Generex Biotechnology plans to initiate a clinical trial for regulatory approval in USA [1] Updated 16 Mar 2020
09 Mar 2020 Phase Change Early research in COVID-2019 infections in China (Parenteral) [1] Updated 09 Mar 2020
09 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (Parenteral) [1] Updated 09 Mar 2020
02 Mar 2020 Licensing Status Beijing Zhonghua Investment Fund Management and Sinotek-Advocates International Industry Development in-licenses coronavirus vaccine from Generex Biotechnology in China [1] Updated 12 Mar 2020
16 Aug 2019 Company Involvement Generex Biotechnology announced a spin-out of its subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express) [2] Updated 12 Mar 2020

References

  1. Generex Signs Contract with Chinese Partners Beijing Zhonghua Investment Fund Management Co., LTD and Sinotek-Advocates International Industry Development (Shenzhen) Co., Ltd. to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccine Technology.

    Media Release
  2. Generex Biotechnology Announces Plans for NuGenerex Immuno-Oncology Spinout through a Targeted Acquisition of a Public Company and Planned Merger with Kiromic.

    Media Release
  3. Generex Biotechnology Initiates Peptide Manufacturing for Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic.

    Media Release
Back to top